Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial - Trial NCT04265950
Access comprehensive clinical trial information for NCT04265950 through Pure Global AI's free database. This Phase 4 trial is sponsored by Fred Hutchinson Cancer Research Center and is currently Recruiting. The study focuses on HIV Infection. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Fred Hutchinson Cancer Research Center
Timeline & Enrollment
Phase 4
Mar 10, 2022
Jun 30, 2026
Primary Outcome
Human papillomavirus type 16 (HPV16) neutralizing antibody geometric mean titers (GMTs) (Arm 1 versus [vs.] Arm 2)
Summary
This phase IV trial compares 3 different dosing schedules to find the optimal number of doses
 for HPV vaccination in children and adolescents living with HIV. Comparing 3 different dosing
 schedules may help researchers determine whether a single dose of HPV vaccine could be
 effective in preventing HPV in children and adolescents living with HIV.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04265950
Non-Device Trial